Evidence-based·Updated November 19, 2026·How we grade evidence

Elamipretide (SS-31)

PeptidePeptide drug

Elamipretide (Forzinity) is approved only for Barth syndrome, a rare inherited mitochondrial disease, under accelerated approval based on knee muscle strength in a 12-patient program; a confirmatory trial is under way. It did not improve walking distance or fatigue in the randomized part of that program, and trials in more common conditions (primary mitochondrial myopathy, heart failure, dry macular degeneration) missed their main goals. There is no trial showing it slows aging or extends life.

Taking Elamipretide (SS-31) with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

People with genetically confirmed Barth syndrome who weigh at least 30 kg, treated by a specialist with a prescription

Common dosing range

Set by your prescriber. The label dose is 40 mg injected under the skin once daily (20 mg once daily in adults with severe kidney impairment not on dialysis)

When to expect effects

Knee strength gains were seen in the open-label extension, from about 12 weeks onward; none were seen in the 12-week randomized phase

Watch out for

No boxed warning. Serious allergic reactions have been reported and rule out further use; injection-site reactions are very common; it contains benzyl alcohol and is not for newborns. It is approved only for Barth syndrome: products sold as "SS-31" for longevity are unapproved and unverified

What is it

Elamipretide (also called SS-31, and in early trials MTP-131 or Bendavia) is a small peptide given as an injection under the skin. It is FDA-approved under the brand name Forzinity (Stealth BioTherapeutics) for one use only: to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Barth syndrome is a rare, X-linked genetic disease of the mitochondria, the parts of cells that make energy. FDA granted accelerated approval on September 19, 2025, based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint, and the label says continued approval may be contingent on a confirmatory trial; FDA required a randomized, placebo-controlled trial in patients 5 years and older, and a 72-week placebo-controlled trial is recruiting. Elamipretide is not approved for aging, "longevity", energy or any other mitochondrial condition. In larger trials in primary mitochondrial myopathy, heart failure and dry macular degeneration it did not meet its main goals, and in published trials in healthy older adults it has only been given as a single dose. Vials sold online as "SS-31" for research are not Forzinity and are not FDA-approved.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You or your child has genetically confirmed Barth syndrome, weighs at least 30 kg, and a specialist recommends it with a prescription
You understand that approval rests on knee muscle strength, not yet on proven gains in walking, fatigue or survival, and you plan follow-up with your prescriber
You are interested in other uses and qualify for a registered clinical trial that is recruiting (ClinicalTrials.gov lists one in adults aged 65 to 80), rather than using it on your own

Probably skip if…

You have had a serious allergic reaction to elamipretide or any ingredient in Forzinity (it is contraindicated)
You want it for anti-aging, longevity, energy or exercise performance: no trial has shown these benefits, and it is not approved for them
You would be buying "SS-31" vials, nasal sprays or capsules online: these are not Forzinity and their content is unverified
You are on dialysis or the patient weighs under 30 kg, unless a specialist decides otherwise: the label says there is not enough information to recommend a dose

Evidence at a glance

walking and fatigue in primary mitochondrial myopathy

Good Evidence
Effect
6-minute walk -3.2 m versus placebo (95% CI -18.7 to 12.3); no change in fatigue
Best fit
None shown in this trial
Time
No benefit at 24 weeks

muscle strength and walking in Barth syndrome

Limited Evidence
Effect
Median knee strength +63 newtons at week 168 in 8 patients (no control group); no difference from placebo in the 12-week randomized phase
Best fit
People with genetically confirmed Barth syndrome aged 12 and older weighing at least 30 kg
Time
Strength gains appeared from about 12 weeks into the open-label extension

heart function in heart failure with reduced ejection fraction

Limited Evidence
Effect
No difference from placebo in heart volume or ejection fraction at 4 weeks
Best fit
None shown in this trial
Time
No benefit at 4 weeks

vision and lesion growth in dry age-related macular degeneration

Limited Evidence
Effect
Primary endpoints not met; secondary ellipsoid zone loss 43% slower (nominal)
Best fit
Under study in dry macular degeneration in the ongoing phase 3 trial
Time
Not established

muscle energy production in older adults (the basis of "longevity" use)

Mixed Evidence
Effect
Short-lived rise in muscle ATP production after one infusion; no change in fatigue resistance
Best fit
Research participants only
Time
Immediately after one infusion; gone by day 7

Evidence for 5 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

walking and fatigue in primary mitochondrial myopathy

No benefit found
Good Evidence

MMPOWER-3, a phase 3 trial, randomized 218 adults with genetically confirmed primary mitochondrial myopathy (mean age 45.6, 64% women) to 40 mg daily or placebo for 24 weeks. It did not meet its main goals: the difference in 6-minute walk distance was -3.2 m (95% CI -18.7 to 12.3; p = 0.69), and fatigue scores did not differ (p = 0.37). The drug was well tolerated, with mostly mild to moderate adverse events.

Effect size
6-minute walk -3.2 m versus placebo (95% CI -18.7 to 12.3); no change in fatigue
Time to effect
No benefit at 24 weeks
Best fit
None shown in this trial
Less likely
Adults with primary mitochondrial myopathy

Bottom line: The largest trial of elamipretide in a mitochondrial disease found no improvement in walking or fatigue.

muscle strength and walking in Barth syndrome

Disease adjunct
Limited Evidence

In the TAZPOWER trial, 12 males aged 12 to 35 with genetically confirmed Barth syndrome took 40 mg daily or placebo for 12 weeks each, in random order, with a 4-week break between. Neither main goal (6-minute walk distance and a fatigue score) improved, and the label reports no increase in knee strength in the randomized phase (median change +4 newtons on elamipretide versus -5 on placebo). Ten patients then took it in an open-label extension. The FDA label reports that, from a median starting strength of 124 newtons, knee strength rose by a median of 34 newtons at week 12 of the extension and 63 newtons at week 168 (8 patients). In the papers, walk distance improved by 95.9 m at 36 weeks (8 patients) and by a cumulative 96.1 m at week 168. The extension had no placebo group, the numbers are very small, the manufacturer funded the trial and helped design it and analyze the data, and one author was a company employee. FDA accepted knee strength as an intermediate endpoint for accelerated approval and required a confirmatory randomized trial.

Effect size
Median knee strength +63 newtons at week 168 in 8 patients (no control group); no difference from placebo in the 12-week randomized phase
Time to effect
Strength gains appeared from about 12 weeks into the open-label extension
Best fit
People with genetically confirmed Barth syndrome aged 12 and older weighing at least 30 kg
Less likely
People without Barth syndrome; children under 30 kg, who were not studied

Bottom line: Strength and walking improved over years of open-label use, but the randomized phase showed no benefit, so the confirmatory trial matters.

Evidence is mixed

In the double-blind, placebo-controlled phase, elamipretide was not better than placebo on walk distance, fatigue or knee strength. The improvements come from the uncontrolled extension, where expectation and practice effects cannot be ruled out.

heart function in heart failure with reduced ejection fraction

No benefit found
Limited Evidence

The PROGRESS-HF phase 2 trial randomized 71 adults with stable heart failure (ejection fraction 40% or less, mean age 65) to placebo, 4 mg or 40 mg daily for 28 days. Heart volume on MRI (left ventricular end-systolic volume) did not change compared with placebo (40 mg versus placebo: difference 2.3 mL, 95% CI -1.9 to 6.5; P = 0.28), and neither did ejection fraction. Side effects were similar across groups.

Effect size
No difference from placebo in heart volume or ejection fraction at 4 weeks
Time to effect
No benefit at 4 weeks
Best fit
None shown in this trial
Less likely
Adults with stable heart failure with reduced ejection fraction

Bottom line: Four weeks of elamipretide did not improve heart structure or pumping in heart failure.

vision and lesion growth in dry age-related macular degeneration

No benefit found
Limited Evidence

In the ReCLAIM-2 phase 2 trial, 176 people aged 55 or older with dry macular degeneration and geographic atrophy (after a protocol change, only atrophy away from the center of vision; 27 people with central atrophy had already joined) took 40 mg daily or placebo for 48 weeks. Neither main goal improved: low-light visual acuity and growth of the atrophy area were not significantly different from placebo. In secondary analyses, loss of a light-sensing retinal layer (the ellipsoid zone) progressed 43% less (nominal P = 0.0034), and more people gained 10 or more letters in low light (14.6% versus 2.1%), but these were not the trial's main tests. Adverse events occurred in 86% on elamipretide and 71% on placebo, mostly injection-site reactions. A phase 3 trial is ongoing.

Effect size
Primary endpoints not met; secondary ellipsoid zone loss 43% slower (nominal)
Time to effect
Not established
Best fit
Under study in dry macular degeneration in the ongoing phase 3 trial
Less likely
Anyone hoping to protect vision now: no benefit on vision has been confirmed

Bottom line: It missed its main vision goals; a hint on a retinal scan measure is being tested in a phase 3 trial.

Evidence is mixed

The secondary retinal-layer and letter-gain results favored elamipretide, but the primary endpoints were not met, so these signals need confirmation.

muscle energy production in older adults (the basis of "longevity" use)

Biomarker support
Mixed Evidence

In this randomized, placebo-controlled trial, 39 healthy adults aged 60 to 85 (46% women), chosen because their muscle mitochondria worked poorly, received a single 2-hour intravenous infusion of elamipretide or placebo. Right after the infusion, the maximum energy (ATP) production of a hand muscle rose compared with placebo (P = 0.045 for percent change), but the effect was gone at day 7, and the muscle did not resist fatigue any better. The manufacturer funded the work and worked with the authors on its design, and three authors had been paid consultants to the company from 2014 to 2016. A 4-week safety study of daily injections in 30 adults aged 65 to 80 is recruiting. No trial has tested whether elamipretide improves strength, function, disease or lifespan in aging people.

Effect size
Short-lived rise in muscle ATP production after one infusion; no change in fatigue resistance
Time to effect
Immediately after one infusion; gone by day 7
Best fit
Research participants only
Less likely
Healthy people using it for anti-aging, energy or performance

Bottom line: One infusion briefly changed a lab measure of muscle energy in older adults; there is no evidence that it slows aging.

How it works

The Forzinity label calls elamipretide a mitochondrial cardiolipin binder: it collects in the inner membrane of the mitochondria and improves their shape and function. Cardiolipin is a fat that this membrane needs to make energy efficiently. In Barth syndrome, a defect in the TAZ gene makes cardiolipin abnormal, which is why the drug was tested there first. After an injection under the skin, blood levels peak within 0.5 to 1 hour and about 92% of the dose is absorbed. It is broken down into inactive pieces and leaves the body in the urine, almost all of it within 48 hours in people with normal kidneys. Exposure rises when kidney function is reduced (by 125% in severe kidney impairment), which is why the label halves the dose in that group. It is not processed by the liver enzymes that handle most drugs.

How to take it

1. Typical dose
Your prescriber sets the dose. The Forzinity label dose for patients weighing at least 30 kg is 40 mg (0.5 mL) injected under the skin once daily. For adults with severe kidney impairment (eGFR under 30 mL/min) who are not on dialysis, the label dose is 20 mg once daily. The label says there is not enough information to recommend a dose for adults with eGFR under 30 mL/min who are on dialysis, or for children weighing 30 kg or more who have kidney impairment, and it is not approved for children under 30 kg.
2. Higher studied dose
40 mg once daily is the maximum recommended dose. The label notes that exposure rises in proportion to the dose between 2 and 80 mg, and that no clinically significant QT prolongation was seen at 3 times the peak level of the maximum dose.
3. Timing
Once a day at the same time each day. If a dose is missed, the label says to skip it and take the next dose at the usual time, never a double dose.
4. With food
It is an injection, so food timing does not apply; the label gives no food instructions.
5. Split dosing
Not used; it is a single daily injection.
6. How long to try
Long-term daily use, as your prescriber decides. In the Barth syndrome program, some patients used it for up to 192 weeks. Inject in the abdomen (at least 2 inches from the navel) or outer thigh, rotate sites daily, and throw away each vial 8 days after first opening.

What to track

Redness, pain, hardening, itching, bruising or hives at injection sites (very common; ask your prescriber about antihistamines or steroid creams)
Rash, hives, cough, wheezing, swelling or trouble breathing, which can mean a serious allergic reaction: the label tells patients to stop it and get immediate medical help
Blood tests your prescriber orders: the label notes that eosinophil counts often rise for a few months and then return to baseline
Kidney function, since severe kidney impairment changes the dose
Muscle strength and daily function at the visits your specialist schedules

Bottom line: A daily injection for Barth syndrome only; your prescriber sets the dose, and it is not an anti-aging product.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Injection-site reactions, which occurred in all 12 patients on elamipretide versus 8 of 12 (67%) on placebo in the Barth syndrome trial: redness (100% versus 25%), pain (75% versus 42%), hardening (67% versus 17%), itching (67% versus 17%), bruising (25% versus 0) and hives (25% versus 0)Rise in eosinophils (a type of white blood cell) on blood tests, usually peaking around 90 days and returning to baseline after 6 to 12 months, without symptomsSkin reactions such as rash, bumps and eczema-like patches, which the label lists among allergic reactions

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the label says there are no data on use in pregnant women, because Barth syndrome is an X-linked disease that is not likely to affect females. Animal studies in rats and rabbits found no harm to development at exposures up to about 4 to 10 times the human dose, and benzyl alcohol is unlikely to reach the fetus. Breastfeeding: the label says there are no data on whether it passes into breast milk or affects a breastfed baby or milk production, and benzyl alcohol exposure through milk is unlikely. Decisions go to your doctor.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Brand name Forzinity (elamipretide) injection, made for Stealth BioTherapeutics, dispensed with a prescription in your name
Single-patient vials of 280 mg in 3.5 mL (80 mg/mL), four vials per carton (NDC 72507-800-04); the solution is clear and colorless to yellow
Comes with FDA-approved Instructions for Use; unopened vials are kept in the refrigerator, and opened vials are discarded 8 days after first use
Do not use a vial that is cloudy, discolored, contains particles, or is cracked

Be skeptical of…

"SS-31 for longevity, anti-aging or mitochondrial energy": no trial has shown these benefits, and the only approved use is Barth syndrome
Vials labeled "for research use only" or "not for human consumption": these are not Forzinity and are not FDA-approved
"FDA-approved SS-31" on a product that is not Forzinity from its manufacturer
Nasal sprays, capsules or creams of SS-31: the only approved form is an injection under the skin
"Proven to boost stamina or endurance": walk distance did not improve versus placebo in either randomized trial that tested it
"No side effects": injection-site reactions occurred in every patient in the Barth trial, and serious allergic reactions have been reported

Frequently asked questions

Is elamipretide FDA-approved?⌄

Yes, for one use. FDA granted accelerated approval to Forzinity (elamipretide) on September 19, 2025, to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. The approval is based on knee muscle strength, and FDA requires a randomized, placebo-controlled trial to confirm that patients benefit. It is not approved for any other condition.

Does elamipretide (SS-31) work for longevity or anti-aging?⌄

That has not been shown, and it is not approved for these uses. The published randomized trial in healthy older adults gave a single infusion and found a short-lived rise in a lab measure of muscle energy, with no change in muscle fatigue. Trials in mitochondrial myopathy, heart failure and dry macular degeneration did not meet their main goals. A small safety study of daily injections in people aged 65 to 80 is recruiting. Ask your doctor about approved ways to address the problem you are trying to solve.

Is the "SS-31" sold online the same as Forzinity?⌄

No. Forzinity is the only FDA-approved elamipretide product. Vials or sprays sold online as SS-31 for research are not checked by FDA for identity, purity, dose or sterility, and their labels often say they are not for human use.

Can I take elamipretide with my supplements or other medicines?⌄

There are no studies of elamipretide with supplements. In lab tests it did not block or speed up the main liver enzymes that break down other drugs, and in studies with aspirin, clopidogrel and heparin it did not change how those drugs worked. In lab tests it blocked a kidney transporter called MATE1, and the label does not say whether this matters for other medicines. Ask your doctor or pharmacist to check your full list.

What are the main side effects?⌄

Injection-site reactions such as redness, pain, hardening, itching, bruising and hives are very common. Eosinophil counts on blood tests often rise for a few months. Serious allergic reactions have been reported: get emergency care for trouble breathing, swelling or widespread rash.

Why was it approved if the trial missed its main goals?⌄

In the 12-week randomized phase, elamipretide did not beat placebo on walk distance or fatigue. FDA granted accelerated approval because knee strength improved during long-term open-label use, a measure it considered reasonably likely to predict benefit such as easier standing or longer walking. The label says continued approval may be contingent on a confirmatory trial; a 72-week placebo-controlled study is recruiting.

References by claim

muscle strength and walking in Barth syndrome

Reid Thompson et al., 2021 · PMC (2021) link

Thompson et al., 2024 · PubMed (2024) link

walking and fatigue in primary mitochondrial myopathy

Karaa et al., 2023 · PMC (2023) link

heart function in heart failure with reduced ejection fraction

Butler et al., 2020 · PubMed (2020) link

vision and lesion growth in dry age-related macular degeneration

Ehlers et al., 2025 · PMC (2025) link

muscle energy production in older adults (the basis of "longevity" use)

Roshanravan et al., 2021 · PMC (2021) link

Safety

Forzinity (elamipretide) prescribing information · DailyMed (FDA label) link

Drugs@FDA: Forzinity, NDA 215244 · FDA link

FDA: Compounding and the FDA, questions and answers · FDA link

FDA: FDA grants accelerated approval to first treatment for Barth syndrome (September 19, 2025) · FDA link

Track Elamipretide (SS-31) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.